Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Ramipril

ACE inhibitor (antihypertensive)

Brand names: Altace

Oral health effects

  • Angioedema

    Class effect: orofacial/airway swelling.

    Mechanism: Bradykinin accumulation from ACE inhibition.

    Clinical management: Emergency management if airway involved; refer for review.

  • Persistent dry cough (ACE inhibitor cough)

    A dry, tickly, non-productive cough is a class effect of ACE inhibitors caused by bradykinin accumulation; it can start weeks to months after starting and resolves within days to weeks of stopping. Label: increased cough in almost 12% of ramipril patients in a 1-year study; 8% vs 4% placebo in the AIRE trial; cough was the most common reason for discontinuation (1.0%).

    Clinical management: Ask about chronic cough at medical history review. Cough can be triggered by water spray, prophy paste or supine positioning: use high-volume suction, a more upright chair position and short breaks. Persistent cough is a reason for the patient to discuss alternatives (e.g. an ARB) with their prescriber; do not advise stopping the medication.

  • Taste disturbance (dysgeusia)

    Taste disturbance (and, less often, increased salivation or dry mouth) is listed among less common (<1%) adverse reactions on the ramipril label; altered taste is a recognised ACE-inhibitor class effect.

    Clinical management: Ask about altered or metallic taste; reassure that it is usually reversible. Encourage good oral hygiene and hydration, and suggest the patient mention persistent taste change to their prescriber.

Sources

  1. Adverse drug events in the oral cavity. Yuan A, Woo SB. Oral surgery, oral medicine, oral pathology and oral radiology, 2015.
  2. Ramipril prescribing information (FDA label) Proficient Rx LP / DailyMed, 2022.
  3. Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis. Hu Y, Liang L, Liu S, Kung JY, Banh HL. Journal of clinical hypertension (Greenwich, Conn.), 2023.
  4. Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials. Vukadinović D, Vukadinović AN, Lavall D, Laufs U, Wagenpfeil S, Böhm M. Clinical pharmacology and therapeutics, 2019.